Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from HilleVax, Inc ( (HLVX) ) is now available.
On June 23, 2025, HilleVax, Inc. held its Annual Meeting of Stockholders where key decisions were made, including the election of Class III directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal 2025. These decisions are crucial for the company’s governance and financial auditing processes, impacting its operational stability and stakeholder confidence.
The most recent analyst rating on (HLVX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on HilleVax, Inc stock, see the HLVX Stock Forecast page.
Spark’s Take on HLVX Stock
According to Spark, TipRanks’ AI Analyst, HLVX is a Underperform.
HilleVax, Inc.’s stock score reflects significant risks due to its financial instability and absence of revenue. While technical indicators suggest some short-term momentum, the company’s reliance on external funding and negative cash flows present substantial challenges. The negative valuation metrics further indicate high risk, typical for early-stage biotech firms.
To see Spark’s full report on HLVX stock, click here.
More about HilleVax, Inc
HilleVax, Inc. operates in the biotechnology industry, focusing on developing vaccines and treatments for infectious diseases.
Average Trading Volume: 259,617
Technical Sentiment Signal: Sell
Current Market Cap: $94.27M
See more insights into HLVX stock on TipRanks’ Stock Analysis page.